Overview

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).
Phase:
Phase 2
Details
Lead Sponsor:
Betaliq, Inc.
Collaborators:
Summit Analytical, LLC
Trial Runners, LLC
Treatments:
Nebivolol
Ophthalmic Solutions
Timolol